Three Nuclear Medicine diagnostic procedures and breast cancer mortality in women. A population-analysis in Taiwan based upon National Health Insurance database.

  title={Three Nuclear Medicine diagnostic procedures and breast cancer mortality in women. A population-analysis in Taiwan based upon National Health Insurance database.},
  author={Mao-chin Hung and Yu Huang},
  journal={Hellenic journal of nuclear medicine},
  • M. Hung, Yu Huang
  • Published 2019
  • Medicine
  • Hellenic journal of nuclear medicine
OBJECTIVE To investigate the correlation between the utilization of nuclear medicine diagnostic procedures and the mortality of women with breast cancer. SUBJECTS AND METHODS Based on the National Health Insurance Research Database (NHIRD), we studied female breast cancer patients in 2012 who underwent whole-body bone scan, lymphoscintigraphy, or fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) for possibly managing breast cancer metastases. The… 

Figures and Tables from this paper

18F-FDG PET/CT Did Not Increase the Risk of Cataract Occurrence in Oncology Patients: A Nationwide Population-Based Cohort Study
It was revealed that 18F-FDG PET/CT was not a significant risk factor for developing cataracts in oncology patients, and the incidence of cataract formation was not significantly higher among subjects in Group E.


Baseline staging tests in primary breast cancer: a practice guideline.
The Breast Cancer Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative reviewed the evidence and indications for routine bone scanning, liver ultrasonography and chest radiography in asymptomatic women who have undergone surgery for breast cancer to recommend the following recommendations to women with newly diagnosed breast cancer.
Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer
Background Bone scintigraphy is the standard procedure for the detection of bone metastases in breast cancer patients. FDG-PET/CT has been reported to be a sensitive tool for tumor staging in
Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications.
It is indicated that a complete diagnostic work-up to detect metastases is unnecessary in the majority of patients with newly diagnosed breast cancer, whereas it may be indicated for specific patient categories such as those with stage III disease.
Staging of Breast Cancer: New Recommended Standard Procedure
The findings suggest that breast cancer patients can be divided into two subgroups: first group pT1-3N0-1, with ≤3 involved nodes, and second group p t1- 3N1 with ≥4 involved node, pT4 and pN2 (metastases detection rate 1.46 and 10.68%, respectively).
[Nuclear Medicine in diagnosis of breast cancer].
Modern research focusing on the development of new specific functional breast imaging methods improves diagnostic and therapeutic management of patients with breast cancer.
The role of (18)F-FDG PET/CT in initial staging of patients with locally advanced breast carcinoma with an emphasis on M staging.
It is suggested that more extra axillary lymph nodal and distant metastases can be identified by (18)F-FDG PET/CT as compared to a group of clinical, X-rays, ultrasound and bone scan examinations together.
Whole body bone SPET/CT can successfully replace the conventional bone scan in breast cancer patients. A prospective study of 257 patients.
Whole-body bone SPET/CT scan outperformed WBS in terms of sensitivity, accuracy, positive and negative predictive value and impacted on patient management, therefore, its use is recommended as a routine procedure in BC patients, even after a negative WBS.
Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.
Among patients with limited SLN metastatic breast cancer treated with breast conservation and systemic therapy, the use of SLND alone compared with ALND did not result in inferior survival, and overall survival was the primary end point, with a noninferiority margin of a 1-sided hazard ratio of less than 1.3 indicating thatSLND alone is noninherited.
Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.
Gamma-probe guided localization of lymph nodes.